Genedrive PLC Directorate Change (2405K)
April 09 2018 - 3:06AM
UK Regulatory
TIDMGDR
RNS Number : 2405K
Genedrive PLC
09 April 2018
For release: 9 April 2018
genedrive plc ("genedrive" or the "Company")
genedrive appoints Tom Lindsay as Non-Executive Director
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, today announces that it has appointed Tom Lindsay as a
Non-Executive Director with immediate effect.
Tom has 35 years of global sales and marketing experience in the
diagnostics sector. He most recently worked for Alere Inc. in
Africa for 11 years before retiring in 2017. At Alere he held a
range of executive posts including President of Africa, President
Commercial Operations for Africa, and Business Development Director
for Africa; and led the introduction and successful
commercialisation of a number of key HIV screening and HIV patient
management point of care diagnostics technologies.
Prior to joining Alere Inc., Tom held senior commercial roles at
Trinity Biotech (Ireland) including Marketing and Sales Director
(Global) and Business Development Director for Africa, Middle East
and India. Trinity Biotech specialises in the development,
manufacture and marketing of diagnostic test kits.
Tom studied Microbiology at Glasgow Caledonian University and
completed a National Diploma in Microbiology at the South African
Institute of Medical Research in Johannesburg, South Africa.
Ian Gilham, Non-Executive Chairman of genedrive, said: "Tom has
exceptionally strong experience in commercialising diagnostics in
Africa and other low and middle income markets. We look forward to
working with him as we continue to deliver on the opportunities
presented by our Genedrive(R) HCV ID test, which is the first
decentralised test to market, and by the Genedrive(R) platform more
widely."
Tom Lindsay said: "The simplicity, low-cost, speed and
versatility of the Genedrive(R) platform represent significant
strengths for decentralised molecular diagnostics. I am excited to
join the Board and about the prospects for Genedrive(R) across
multiple indications and markets."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: Thomas Lindsay (aged 60)
Tom Lindsay does not currently hold any shares in genedrive
plc.
Current Directorships or Partnerships:
None
Previous Directorships or Partneships in the last five
years:
Alere Healthcare Pty Ltd
Pantech Pty Ltd
Alere Nigeria Ltd
Vision Biotech Pty Ltd
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
- Ends -
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP +44 (0)207 418 8900
James Steel
Oliver Jackson
Consilium Strategic Communications +44 (0)203 709 5700
Chris Gardner
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Stanford Capital Partners
Limited +44 (0)203 815 8880
Patrick Claridge
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF assay has been
launched in India and a Genedrive(R) HCV test has received CE-IVD
Certification and has been launched in Africa. genedrive has
distribution agreements with subsidiaries of Sysmex Corporation for
the distribution of the Genedrive(R) platform in the EMEA and Asia
Pacific regions, and with ARKRAY Healthcare pvt Ltd for the
distribution of the Genedrive(R) HCV ID Kit and Genedrive(R)
platform in India.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUKRWRWOASRRR
(END) Dow Jones Newswires
April 09, 2018 04:06 ET (08:06 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024